Y-Mabs Therapeutics Total Current Liabilities

Y-Mabs Therapeutics (YMAB) currently reports a total current liabilities of $23M as of June 2025. That compares with $43M in the prior-year period — down 47.2% year over year. Use the charts on this page to explore Y-Mabs Therapeutics's total current liabilities history and peer comparisons.

Y-Mabs Therapeutics's total current liabilities decreased from $43M to $23M — a 47.2% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Y-Mabs Therapeutics reported $23M in total current liabilities as of June 2025. That compares with $43M in the prior-year period — down 47.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $23M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Y-Mabs Therapeutics, and consider following YMAB for alerts when major investors trade the stock.

Y-Mabs Therapeutics is classified in the Healthcare sector. On total current liabilities, it currently shows $23M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing YMAB with unrelated industries.